These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16117995

  • 21. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV.
    Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
    [Abstract] [Full Text] [Related]

  • 22. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

  • 23. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 24. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators.
    Circulation; 2005 Sep 06; 112(10):1428-34. PubMed ID: 16129801
    [Abstract] [Full Text] [Related]

  • 25. Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
    Gandjour A, Ostwald DA.
    Pharmacoeconomics; 2018 Oct 06; 36(10):1285-1296. PubMed ID: 30054868
    [Abstract] [Full Text] [Related]

  • 26. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 06; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 27. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M, Schein J, Mody S, Grant R, Benson C, Olson W.
    Curr Med Res Opin; 2009 Sep 06; 25(9):2151-7. PubMed ID: 19601711
    [Abstract] [Full Text] [Related]

  • 28. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Sep 06; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 29. Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.
    Peters S, Trümmel M, Meyners W, Koehler B, Westermann K.
    Int J Cardiol; 2005 Feb 15; 98(2):331-5. PubMed ID: 15686787
    [Abstract] [Full Text] [Related]

  • 30. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 31. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ, Migliaccio-Walle K, O'Brien JA, Nova W, Kim J, Hauch O, Hillson E, Wedel H, Hjalmarson A, Gottlieb S, Deedwania PC, Wikstrand J, MERIT-HF Study Group.
    J Card Fail; 2005 Dec 16; 11(9):647-56. PubMed ID: 16360958
    [Abstract] [Full Text] [Related]

  • 32. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs.
    Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL.
    Ann Pharmacother; 2005 Nov 16; 39(11):1785-91. PubMed ID: 16219900
    [Abstract] [Full Text] [Related]

  • 33. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 34. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May 15; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 35. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, Val-HeFT Investigators.
    Congest Heart Fail; 2010 May 15; 16(5):191-5. PubMed ID: 20887614
    [Abstract] [Full Text] [Related]

  • 36. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Vachiéry JL.
    Rev Med Brux; 2003 Sep 15; 24(4):A249-52. PubMed ID: 14606288
    [Abstract] [Full Text] [Related]

  • 37. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ.
    Nat Clin Pract Cardiovasc Med; 2005 Mar 15; 2(3):128-9. PubMed ID: 16265452
    [No Abstract] [Full Text] [Related]

  • 38. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 15; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 39. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C.
    Eur J Heart Fail; 2013 Nov 15; 15(11):1236-44. PubMed ID: 23787721
    [Abstract] [Full Text] [Related]

  • 40. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 Nov 15; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.